Fusion Net Income From Continuing Ops from 2010 to 2026
| FSPM Stock | USD 0.0001 0.00 0.00% |
Net Loss | First Reported 2010-12-31 | Previous Quarter -37.9 K | Current Value -36 K | Quarterly Volatility 73.3 K |
Check Fusion Pharm financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Fusion Pharm's main balance sheet or income statement drivers, such as Discontinued Operations of 0.0, Interest Expense of 0.0 or Selling General Administrative of 164 K, as well as many indicators such as . Fusion financial statements analysis is a perfect complement when working with Fusion Pharm Valuation or Volatility modules.
Fusion | Net Income From Continuing Ops | Build AI portfolio with Fusion Stock |
Evaluating Fusion Pharm's Net Income From Continuing Ops across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Fusion Pharm's fundamental strength.
Latest Fusion Pharm's Net Income From Continuing Ops Growth Pattern
Below is the plot of the Net Income From Continuing Ops of Fusion Pharm over the last few years. It is Fusion Pharm's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Fusion Pharm's overall financial position and show how it may be relating to other accounts over time.
| Net Income From Continuing Ops | 10 Years Trend |
|
Net Income From Continuing Ops |
| Timeline |
Fusion Net Income From Continuing Ops Regression Statistics
| Arithmetic Mean | (68,819) | |
| Coefficient Of Variation | (106.54) | |
| Mean Deviation | 45,260 | |
| Median | (42,080) | |
| Standard Deviation | 73,319 | |
| Sample Variance | 5.4B | |
| Range | 251.6K | |
| R-Value | 0.53 | |
| Mean Square Error | 4.1B | |
| R-Squared | 0.29 | |
| Significance | 0.03 | |
| Slope | 7,761 | |
| Total Sum of Squares | 86B |
Fusion Net Income From Continuing Ops History
About Fusion Pharm Financial Statements
Fusion Pharm investors utilize fundamental indicators, such as Net Income From Continuing Ops, to predict how Fusion Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Net Loss | -37.9 K | -36 K |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetCheck out the analysis of Fusion Pharm Correlation against competitors. To learn how to invest in Fusion Stock, please use our How to Invest in Fusion Pharm guide.You can also try the Stocks Directory module to find actively traded stocks across global markets.
Will Consumer Staples Distribution & Retail sector continue expanding? Could Fusion diversify its offerings? Factors like these will boost the valuation of Fusion Pharm. Market participants price Fusion higher when confident in its future expansion prospects. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Fusion Pharm data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (0.15) | Revenue Per Share 0.133 | Return On Assets (1.38) |
The market value of Fusion Pharm is measured differently than its book value, which is the value of Fusion that is recorded on the company's balance sheet. Investors also form their own opinion of Fusion Pharm's value that differs from its market value or its book value, called intrinsic value, which is Fusion Pharm's true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Fusion Pharm's market value can be influenced by many factors that don't directly affect Fusion Pharm's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Fusion Pharm's value and its price as these two are different measures arrived at by different means. Investors typically determine if Fusion Pharm is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Meanwhile, Fusion Pharm's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.